Use of sesquiterpene lactone compounds in the manufacture of therapeutic agents for optic neuritis

Sesquiterpene lactone compounds like ACT001 provide a targeted and effective treatment for NMO by inhibiting inflammatory responses, addressing the limitations of current therapies and improving symptom relief in NMO patients.

JP7579027B2Active Publication Date: 2024-11-07ACCENDATECH LUOYANG CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023537447
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-08-28
Publication Date
2024-11-07
Estimated Expiration
2040-08-28

AI Technical Summary

Technical Problem

Current treatments for neuromyelitis optica (NMO) are systemic and have significant side effects, failing to effectively target the autoimmune response and leading to hormonal resistance and treatment ineffectiveness.

Method used

The use of sesquiterpene lactone compounds, particularly Micheliolide derivatives like ACT001, to develop therapeutic drugs that specifically target and inhibit inflammatory responses in NMO, reducing the release of inflammatory factors.

Benefits of technology

ACT001 effectively inhibits the proliferation of microglial cells and reduces the release of inflammatory factors, significantly alleviating NMO symptoms in both in vitro and animal models, offering a safer and more effective treatment alternative to conventional therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579027000006
    Figure 0007579027000006
  • Figure 0007579027000007
    Figure 0007579027000007
  • Figure 0007579027000008
    Figure 0007579027000008
Patent Text Reader

Abstract

The use of a sesquiterpene lactone compound in the manufacture of a therapeutic agent for optic neuritis involves manufacturing a drug containing a sesquiterpene lactone compound and pharmaceutically acceptable adjuvants. According to this study, ACT001 can effectively inhibit the inflammatory response of microglial cells and significantly reduce the release of inflammatory factors, including NO, TNF-α, and IL-6. It also inhibits the proliferation of BV2 cells. It has excellent therapeutic effects on optic neuritis, particularly neuromyelitis optica.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] [Technical field] The present invention relates to the medical field of autoimmune diseases, and specifically relates to the use of sesquiterpene lactone compounds in the preparation of drugs for treating optic neuritis.

[0002] [Background technology] Neuromyelitis optica (NMO) is a demyelinating disease affecting the optic nerve and spinal cord. The disease was first reported in 1872 and was initially thought to be a central nervous system lesion with unifocal onset. There have been many reports of NMO in Asian countries, and there are currently more than 300,000 NMO patients in China alone. In neuro-ophthalmology clinics, the main findings of typical NMO-associated optic neuritis (C-NMO-ON) are simultaneous or successive onset of both eyes, rapid loss of visual acuity with or without eye pain, poor visual recovery, and generally severe visual impairment in both eyes or at least in one eye. On the other hand, recurrent NMO-associated optic neuritis (R-NMO-ON) is often unifocal, prone to recurrence, and partial recovery of visual impairment, although recovery becomes weaker with increasing number of episodes. A significant proportion of spinal cord damage in NMO occurs after vision loss, which can occur days, weeks, months, or even years apart, ultimately leading to paraplegia, sensory and sphincter dysfunction, and in severe cases, respiratory muscle paralysis. Recurrent NMO shares many common features with recurrent optic neuritis in the early clinical symptoms, making it highly susceptible to misdiagnosis as the latter, which delays the timing of treatment, while treatment for optic neuritis worsens the condition of NMO, resulting in more severe outcomes.

[0003] For a long time, there has been debate as to whether NMO is an independent disease or a subtype of multiple sclerosis (MS). Recent studies have shown that serum aquaporin 4 (AQP4) autoantibody (AQP4-Ab) is one of the highly specific indicators for the diagnosis of NMO, and has higher sensitivity (68%-91%) and specificity (85%-99%) in the diagnosis of NMO.

[0004] The uniqueness of NMO is caused by its special pathogenic mechanism. Further studies have shown that AQP4-Ab specifically binds to aquaporin 4 (AQP4) in the endfeet of astrocytes in the central nervous system (CNS). Currently, it is known that the toxic effect of AQP4-Ab on astrocytes can be achieved by two means: complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. According to the latest report by the Verkman research group, NMO-like tissue lesions can be induced by injecting AQP4-Ab into the brain parenchyma. Specific pathological changes include damage to astrocytes, loss of oligodendrocytes, loss of myelin, and apoptosis of neurons. These phenomena are partially similar to the pathological changes occurring in the patient's body, and can therefore be used to study the pathogenic mechanism at the cellular level during the development of NMO. Currently, the relatively unanimous view on the pathogenesis of NMO is that AQP4-Ab first induces the death of astrocytes, then induces demyelinating lesions, and in this process, the abnormal activation of microglia leads to the release of many inflammatory factors, forming the inflammatory pathogenic microenvironment of NMO disease. Research on AQP4 and the discovery of AQP4-Ab have finally allowed us to separate NMO from multiple sclerosis.

[0005] Summary of the Invention [Problem to be solved by the invention] At present, the treatment of NMO mainly includes acute treatment and remission treatment. The acute treatment aims to reduce nervous system dysfunction as much as possible and promote recovery from the disease, and currently mainly includes high-dose methylprednisolone pulse therapy, plasma exchange, intravenous injection of immunoglobulin and cyclophosphamide, etc., while the remission treatment mainly aims to reduce the number of disease relapses and reduce the severity of relapse, and mainly applies immune inhibitors including azathioprine, mycophenolate mofetil, mitoxantrone, methotrexate, rituximab, etc. However, the traditional treatment methods all widely inhibit the immune system of the whole body, reduce the autoimmune reaction of the whole body, cause more systemic side effects to patients, have the risk of inducing severe infection, and the treatment method is easy to induce hormone resistance to make the treatment ineffective.

[0006] Therefore, NMO is suffering from a severe lack of safe and effective drugs to meet clinical needs, and there is an urgent need for research and development of new drugs to treat the disease.

[0007] [Means for solving the problems] technical solution In order to solve the above problems in the prior art, the present invention has invented the use of sesquiterpene lactone compounds in the preparation of drugs for treating optic neuritis through research.

[0008] In another preferred embodiment of the present invention, the optic neuritis is neuromyelitis optica.

[0009] In another preferred embodiment of the present invention, the sesquiterpene lactone compound and a pharma- ceutically acceptable adjuvant are prepared as a medicament.

[0010] In another preferred embodiment of the invention, the medicament is in a liquid, gaseous, solid or semi-solid dosage form.

[0011] In another preferred embodiment of the present invention, the pharmaceutical agent is an injection.

[0012] In another preferred embodiment of the present invention, the pharmaceutical agent is an oral agent.

[0013] In another preferred embodiment of the present invention, the oral preparation is a capsule.

[0014] In another preferred embodiment of the present invention, the oral dosage form is a pill.

[0015] In another preferred embodiment of the present invention, the sesquiterpene lactone compound is a micheliolide derivative.

[0016] [Beneficial Effects of the Invention] Beneficial effects The present invention is the first to use a sesquiterpene lactone compound in the preparation of a drug for treating optic neuritis, and the drug thus prepared has excellent therapeutic effect, especially in the treatment of neuromyelitis optica.

[0017] BRIEF DESCRIPTION OF THE DRAWINGS Description of the drawings FIG. 1 is a structural formula of ACT001 described in an example of the present invention.

[0018] FIG. 2 is a graph showing the results of an experiment on the cytotoxicity of ACT001 to BV-2 cells, as described in an example of the present invention.

[0019] [Figure 3] This shows the inhibition of TNF-α release after BV-2 is activated by LPS by ACT001 described in the Examples of the present invention.

[0020] [Figure 4] A graph showing the inhibition of IL-6 release after BV-2 is activated by LPS by ACT001 described in the Examples of the present invention.

[0021] [Figure 5] A graph showing the inhibition of NO release after BV-2 is activated by LPS by ACT001 described in the Examples of the present invention.

[0022] FIG. 6 is a score diagram showing the alleviation of disease symptoms in Lewis rat NMO model by ACT001 described in the Examples of the present invention.

[0023] [Mode for carrying out the invention] Best Mode for Carrying Out the Invention The present invention will be described in detail below with reference to the drawings, but the description in this part is merely illustrative and interpretive and does not impose any limitations on the scope of the claims of the present invention. In addition, a person skilled in the art can appropriately combine the features in the embodiments and different embodiments in this specification based on the description in this specification.

[0024] Example 1

[0025] The sesquiterpene lactone compound for preparing a therapeutic drug for neuromyelitis optica studied in this example has a structural formula as shown in FIG. 1 and is also called ACT001. The chemical name of ACT001 is (3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate, which is one of the micheliolide derivatives. The structural formula is as shown in FIG. 1. In this example, ACT001 was used to treat and study patients with neuromyelitis optica who were positive for AQP4 autoimmune antibodies.

[0026] The pharmacological efficacy experiments are as follows.

[0027] 1. First, the active ingredients were tested in vitro. The results showed that ACT001 could inhibit the proliferation of BV-2 cells in vitro with an IC50 value of 23.6 μM. At 10 μM, it could significantly reduce the release of inflammatory factors (TNF-α, IL-6, NO) from microglial cells activated by LPS, and reduce the inflammatory response of microglial cells.

[0028] At the same time, prior to constructing an animal model of NMO, first, spinal intrathecal catheter surgery was performed on Lewis rats, and the operation can be performed by controlling the length (7 cm) of the PE10 catheter, so that the outlet can be placed at the position of the first lumbar vertebra of the rat's spinal cord. Lewis rat after spinal intrathecal catheter surgery. On the second day after the operation, the behavior of the rats was the same as that of normal rats, and the rats in which the model was successfully constructed were divided into three groups, and the catheters of the rats in which the catheter was successfully inserted were injected with 10 μL of serum and complement system of NMO patients, and replenished once every four days. As for the administration schedule, the six animals in the model control group were intragastrically administered with saline every day for 15 consecutive days, the eight animals in the hormone group were intragastrically administered with methylprednisolone amber solution for injection at a dose of 30 mg / kg every day for 15 consecutive days, and the six animals in the ACT001 group were intragastrically administered with ACT001 solution at a dose of 60 mg / kg every day for 15 consecutive days. The condition of the animals was observed daily, and behavioral scores were recorded based on the animals' symptoms. The results showed that the animals in the ACT001 group tolerated the disease better, and the disease symptoms were significantly alleviated compared with the saline control group, and the alleviation effect of the ACT001 group was similar compared with the hormone treatment group, with the overall score being almost the same.

[0029] ACT001 was then used to treat neuromyelitis optica. ACT001 can effectively inhibit the inflammatory response of microglial cells and significantly reduce the release of inflammatory factors including NO, TNF-α, and IL-6. First, the effect of ACT001 on the proliferation activity of microglial cells BV2 was evaluated by in vitro MTT and CCK8 methods. The results showed that ACT001 has the effect of inhibiting the proliferation of BV2 cells in vitro. Specifically, the IC value of ACT001 on BV2 cells was 1.01 mg / kg / day, as shown in Table 1 and Figure 2. 50 The value is 23.6±2.34 μM.

[0030] [Table 1]

[0031] 2. Inhibitory effect of ACT001 on BV2 cells in vitro BV2 cells were digested, counted, and inoculated into a 24-well plate at 1 mL per well, 20,000 cells, and cultured overnight in a 5% CO2, 37°C incubator. All wells were treated with 1 μg / mL LPS for 1 h, and then different concentrations of ACT001 were added to them. Five experimental groups were set up: (1) control group, (2) ACT001-2.5 μM group, (3) ACT001-5 μM group, (4) ACT001-10 μM group, and (5) ACT001-20 μM group. After 8 h, the supernatant was collected and centrifuged at 12,000 rpm for 20 min, and ELISA was performed according to the procedure in the instruction manual of the reagent kit.

[0032] Figure 2 shows the effect of ACT001 on the proliferation activity of BV2 cells. As can be seen from Figure 2, compared with the control group, all ACT001 groups were able to reduce the expression of IL-6 in BV-2 cells, and as the effective dose of ACT001 increased, the inhibitory effect on IL-6 became stronger and was dose-dependent. Compared with the control group, the 10 μM and 20 μM dose groups of ACT001 both had p values ​​less than 0.001, i.e., a very significant decrease, and the trend was consistent in three repeated runs.

[0033] 3. Effect of ACT001 on IL-6 expression

[0034] BV2 cells were digested, counted, and inoculated into a 24-well plate at 1 mL per well, 40,000 cells, and cultured overnight in a 5% CO2, 37°C incubator. All wells were treated with 1 μg / mL LPS for 1 h, and then different concentrations of ACT001 were added to them. Five experimental groups were set up: (1) control group, (2) ACT001-2.5 μM group, (3) ACT001-5 μM group, (4) ACT001-10 μM group, and (5) ACT001-20 μM group. After 24 h, the supernatant was collected and centrifuged at 12,000 rpm for 20 min, and ELISA was performed according to the procedure in the instruction manual of the reagent kit.

[0035] Figure 3 shows the effect of ACT001 on IL-6 expression (*P<0.05, **P<0.01, ***P<0.001). As can be seen from Figure 3, compared with the control group, all ACT001 groups can reduce the expression of TNF-α in BV-2 cells, and as the effective dose of ACT001 increases, the inhibitory effect on TNF-α becomes stronger and dose-dependent. Compared with the control group, all ACT001-dosed groups have a p value less than 0.001, that is, a very significant decrease, and the trend is consistent after three repetitions.

[0036] 4. Effect of ACT001 on TNF-α expression

[0037] BV2 cells were digested, counted, and inoculated into a 24-well plate at 1 mL per well, 40,000 cells, and cultured overnight in a 5% CO2, 37°C incubator. All wells were treated with 1 μg / mL LPS for 1 h, and then different concentrations of ACT001 were added to them. Five experimental groups were set up: (1) control group, (2) ACT001-2.5 μM group, (3) ACT001-5 μM group, (4) ACT001-10 μM group, and (5) ACT001-20 μM group. After 24 h, the supernatant was collected and centrifuged at 12,000 rpm for 20 min, and ELISA was performed according to the procedure in the instruction manual of the reagent kit.

[0038] Figure 4 shows the effect of ACT001 on the expression of TNF-α (*P<0.05, **P<0.01, ***P<0.001). As can be seen from Figure 4, compared with the control group, the 2.5 μM, 5 μM, and 10 μM dose groups of ACT001 can all reduce the expression of NO in BV-2 cells, and as the effective dose of ACT001 increases, the inhibitory effect becomes stronger and is dose-dependent, among which the 10 μM dose group of ACT001 shows an extremely significant reduction compared with the control group.

[0039] 5. Figure 5 shows the effect of ACT001 on the expression of NO (*P<0.05, **P<0.01, ***P<0.001). As can be seen from Figure 5, ACT001 can significantly reduce the pathological release of microglial NO at a concentration of 5 μM.

[0040] 6. Effects of ACT001 on in vitro studies in NMO patients and animal models

[0041] The rats that had successfully undergone spinal intrathecal catheter surgery were injected with 10 μL of serum and complement from NMO patients into the catheter, and the catheter was replenished once every four days to establish an animal model of NMO. The model animals were randomly divided into three groups: a saline group, a hormone (methylprednisolone sodium succinate for injection) group, and an ACT001 group, with the following administration schedule:

[0042] [Table 2] That is, the dose in group B corresponds to approximately 5 mg / kg, which is the dose of ACT001 administered to the human body after being formulated from ACT001 and pharma- ceutically acceptable excipients, and the dose in group C corresponds to approximately 10 mg / kg, which is the dose of ACT001 administered to the human body after being formulated from ACT001 and pharma- ceutically acceptable excipients.

[0043] The animals were behaviorally scored based on their symptoms.

[0044] The scoring criteria are as follows:

[0045] 0 points: No clinical symptoms.

[0046] Score 1: Decreased tail tone or slight awkwardness in gait.

[0047] Score 2: No tail tone or moderately abnormal gait, bilateral hind limbs weak, able to recover after being passively turned.

[0048] Score 3: Both hind limbs are paralyzed, unable to recover after being passively turned, but able to move when stimulated.

[0049] 4 points: Both hind legs are paralyzed. Forelimbs are paralyzed or have reduced muscle strength, and there is urinary and fecal incontinence.

[0050] 5 points: Critically ill or dead.

[0051] Symptoms that fall between both criteria are calculated as ±0.5.

[0052] The experimental results showed that during the administration period, the animals in the ACT001 group were well tolerated, and the disease symptoms were significantly alleviated compared with the saline control group, and the ACT001 group had similar alleviation effects and similar behavioral scores compared with the hormone treatment group. The experimental results are shown in Table 2 and Figure 6.

[0053] Table 2. Behavioral scores of animals in each group

[0054] [Table 3] Note: *P<0.05, **P<0.01, ***P<0.001 compared to saline.

[0055] Figure 6 shows the behavioral score of the animal model. As can be seen from Table 2 and Figure 6, ACT001 can significantly reduce the behavioral score of the animal model of NMO, improve the symptoms of the disease model of NMO, and its effect is not inferior to that of hormones.

[0056] Table 3: In vivo pharmacodynamic studies [Table 4]

[0057] As can be seen from the above results, ACT001 has significant advantages in the treatment of NMO. Through in vitro activity testing of ACT001, the IC50 value of ACT001 on BV-2 microglial cells was determined to be 23.6 μM, and it can significantly reduce the release of inflammatory factors including NO, TNF-α, and IL-6, and inhibit the inflammatory response of microglial cells induced by LPS stimulation.

[0058] Experimental results in an animal model of neuromyelitis optica showed that ACT001 could significantly alleviate the clinical symptoms of the animal model of neuromyelitis optica, and after 15 days of continuous administration, the behavioral score of the saline group was 3.17±0.26, and the behavioral score of the ACT001 group was 2.00±0.32, which was almost the same as the behavioral score of the hormone group, 2.31±0.26. ACT001 has been shown to be a completely new treatment for NMO disease in clinical practice, replacing hormones.

[0059] ACT001 was initially selected, but in addition to ACT001, according to the above experiments, the derivatives of micheliolide and their salts also have the effect of treating neuromyelitis optica.

[0060] The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principles of the present invention should be equivalent replacement forms, and are all included in the scope of the claims of the present invention. [Brief description of the drawings]

[0061] [Figure 1] 1 is a structural formula of ACT001 described in the examples of the present invention. [Diagram 2] FIG. 1 shows the results of an experiment on the cytotoxicity of ACT001 against BV-2 cells, as described in the Examples of the present invention. [Diagram 3] FIG. 1 shows the inhibition of TNF-α release after BV-2 is activated by LPS by ACT001 described in the Examples of the present invention. [Figure 4] FIG. 1 shows the inhibition of IL-6 release after BV-2 is activated by LPS by ACT001 described in the Examples of the present invention. [Diagram 5] FIG. 1 shows the inhibition of NO release after BV-2 is activated by LPS by ACT001 described in the Examples of the present invention. [Figure 6] FIG. 1 is a score diagram showing the effect of ACT001 described in the examples of the present invention on alleviating symptoms of Lewis rat NMO disease model.

Claims

1. Use of a sesquiterpene lactone compound represented by the following structural formula in the manufacture of a medicament for the treatment of neuromyelitis optica: 【Chemistry 1】 。

2. 2. The use according to claim 1, wherein the medicament is in a liquid, gaseous, solid or semi-solid dosage form.

3. The use according to claim 1 or 2, characterized in that the medicament is an injectable drug.

4. The use according to claim 1 or 2, characterized in that the medicament is an oral agent.

Citation Information

Patent Citations

  • Application of dimethyl amino micheliolide in preparation of anti-aging drugs

    CN111494366A